SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

Jan 10 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing ...

After a 2024 marred by a series of trial failures, Sage Therapeutics Inc. has received an acquisition offer from longtime partner Biogen Inc. on the eve of the biggest biotech event of the year.

BMO Capital says Biogen (BIIB) is looking for an early potential deal by offering to buy Sage Therapeutics (SAGE) for $7.22 per share. Such an offer reflects Biogen’s interest in reducing its ...

Biogen has offered to purchase Sage’s outstanding shares for $7.22 each, according to a securities filing from Friday. The proposal values Sage at around $442 million. A yearslong partner of ...

Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

Companies including Biogen Inc. and Eli Lilly & Co. have spent billions of dollars on developing potential treatments, while others including Novo Nordisk A/S and Roche AG are also investigating ...

Biogen offers $7.22 per share to acquire Sage Therapeutics. Goldman Sachs projects Zurzuvae could reach $700 million in global sales by 2034. Get Pro-Level Earnings Insights Before the Market ...